09/17/2024 12:30 |
DMPK Patent Granted in Japan |
08/13/2024 12:00 |
Modalis Therapeutics to Present Functional Evaluation and Optimization Methodology for AAV Vector Genomes Using Nanopore Sequencing |
08/07/2024 15:30 |
Business and Financial report for the Six Months Ended June 30,2024 |
08/07/2024 15:30 |
Business Plans and Matters Related to High Growth Potential |
08/07/2024 15:30 |
Notice Regarding the Recording of Non-Operating Income(Foreign Exchange Income) |
07/24/2024 12:00 |
Modalis Therapeutics to Present Data on Establishing Manufacturing Process of Muscle Tropic Engineered AAV Vectors |
07/10/2024 15:00 |
Modalis and GENIXCURE enter into Memorandum of Understanding for Research Collaboration to Develop Next-Generation Therapeutics |
07/08/2024 16:00 |
Notice Regarding Determination of Terms and Conditions of Stock Options (Share Acquisition Rights) |
07/01/2024 08:45 |
Modalis Announces updated strategic plan and business consolidation of US operation |
07/01/2024 08:45 |
Notice Regarding Change of the Executive Officer |
06/24/2024 15:00 |
Modalis Therapeutics to Present Data Supporting Development of Transformative Epigenome Editing Medicines for the Treatment of Muscular Dystrophy |
06/14/2024 12:00 |
Notice Regarding Issuance of Stock Options (Share Acquisition Rights) |
05/08/2024 16:00 |
Notice Regarding the Recording of Non-Operating Income (Foreign Exchange Income) |
05/08/2024 16:00 |
Consolidated Financial Results for the Three Months Ended March 31, 2024 [Japanese GAAP] |
05/08/2024 16:00 |
Financial Results for the Three Months Ended March 31, 2024 |
05/07/2024 15:00 |
Modalis Therapeutics Reports Data Supporting Development of a Transformative Epigenome Editing Therapeutic, MDL-101 |
04/30/2024 15:00 |
Modalis Therapeutics to Present Data Supporting Development of Transformative Epigenome Editing Medicines for the Treatment of Muscular Dystrophy |
04/15/2024 15:00 |
Modalis Therapeutics to Present Data Supporting Development of Transformative Epigenome Editing Medicines for the Treatment of Muscular Dystrophy |
04/12/2024 15:00 |
Modalis Announces Partnership with Ginkgo Bioworks |
04/12/2024 15:00 |
Modalis Announces updated strategic plan and business consolidation of US operation |
03/12/2024 15:00 |
Notice of Change in a Major Shareholder |
03/05/2024 08:00 |
Notice of 2024 Annual General Meeting and Meeting Materials |
02/22/2024 15:00 |
Announcement on Reduction in Amounts of Stated Capital and Capital Reserves and Appropriation of Other Capital Surplus |
02/14/2024 15:00 |
Notice Regarding the Variance between consolidated results and results of the previous year, non-consolidated results and results of the previous year |
02/14/2024 15:00 |
Notice Regarding the Recording of Non-Operating Income (Foreign Exchange Income), Extraordinary Income and Extraordinary Loss |
02/14/2024 15:00 |
Financial Results for the Fiscal Year Ended December 31, 2023 |
02/14/2024 15:00 |
Consolidated Financial Results for the Fiscal Year Ended December 31, 2023 [Japanese GAAP] |
12/13/2023 08:30 |
Modalis and JCR Pharmaceuticals enter into joint research agreement |
11/07/2023 16:00 |
Notice Regarding the Recording of Non-Operating Income and Extraordinary Loss |
11/07/2023 16:00 |
Financial Results for the Nine Months Ended September 30, 2023 |
11/07/2023 16:00 |
Consolidated Financial Results for the Nine Months Ended September 30, 2023 [Japanese GAAP] |